Ogenix Receives CE Mark for EPIFLOŽ Oxygen Wound Therapy Device

(PRLEAP.COM) Ogenix, a medical technology company, announced today receipt of the CE Mark for sales and marketing in Europe of its EPIFLO® product line, allowing doctors to treat chronic wounds using a continuous stream of oxygen on a 24 hour basis.

EPIFLO, a 3 ounce portable device which stays with the patient, has demonstrated the ability to effectively heal wounds by delivering oxygen around the clock, resulting in closure of many wounds that have previously failed standard wound care and other therapies.

According to Neil Saffer, Managing Director of Ogenix, "Oxygen in wound care is quickly gaining recognition within the medical community as a safe and highly effective treatment, and is fast becoming part of the standard treatment of many types of wounds. Our device, the EPIFLO, has been responsible for the closure of many wounds, including many severe wounds that previously resulted in scheduled amputations. Not only is it the treatment of choice for many wound care professionals, it is also highly favored by payers for its reduced treatment time and cost reduction."

About Ogenix
Ogenix is a developer, manufacturer, and marketer of small, portable oxygen generation devices used in wound care. For additional information, please refer to their website at www.epiflo.net.

PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy